News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report fourth quarter and full-year 2017
View HTML
Toggle Summary Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced that management is scheduled to
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on January 31, 2018 , that
View HTML
Toggle Summary Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 – $305 million -- -- 16 programs in development -- SAN FRANCISCO , Jan.
View HTML
Toggle Summary Sarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on December 29, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
CAMBRIDGE, Mass. , Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that the pulmonary function
View HTML
Toggle Summary Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
CAMBRIDGE, Mass. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the election of biopharmaceutical
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on November 30, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
-- Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments -- CAMBRIDGE, Mass. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.